


## PRMT5-IN-31

<b>Cat. No.:</b>	HY-155050
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>24</sub> N <sub>2</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	336.43
<b>Target:</b>	Apoptosis; Histone Methyltransferase
<b>Pathway:</b>	Apoptosis; Epigenetics
<b>Storage:</b>	4°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 50 mg/mL (148.62 mM; Need ultrasonic)

Concentration	Mass			
	1 mg	5 mg	10 mg	
1 mM	2.9724 mL	14.8619 mL	29.7239 mL	
5 mM	0.5945 mL	2.9724 mL	5.9448 mL	
10 mM	0.2972 mL	1.4862 mL	2.9724 mL	

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

PRMT5-IN-31 (Compound 3m) is a selective PRMT5 inhibitor (IC<sub>50</sub>: 0.31 μM). PRMT5-IN-31 up-regulates hnRNP E1 protein level. PRMT5-IN-31 occupies the substrate site of PRMT5 and forms essential interactions with amino acid residues. PRMT5-IN-31 has antiproliferative effects against A549 cells by inducing apoptosis and inhibiting cell migration. PRMT5-IN-31 has high metabolic stability on human liver microsomes (T<sub>1/2</sub>: 132.4 min)<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

0.31 μM (PRMT5)<sup>[1]</sup>

### REFERENCES

[1]. Chu WH, et al. Discovery of tetrahydroisoquinolineindole derivatives as first dual PRMT5 inhibitors/hnRNP E1 upregulators: Design, synthesis and biological evaluation. Eur J Med Chem. 2023 Oct 5;258:115625.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA